Polypeptides and polypeptide analogues

• US 5,464,822 A
• Filed: 08/10/1992
• Issued: 11/07/1995
• Est. Priority Date: 06/09/1989
• Status: Expired due to Term

• Current Assignee: Oliver Wiedow
• Original Assignee: Zeneca Incorporated (Astrazeneca PLC)
• Inventors: Christophers, Enno, Schroder, Jens-Michael, Wiedow, Oliver
• Primary Examiner(s): SIDBERRY, HAZEL
• Application Number:
  US07/926,371
• Time in Patent Office: 1,184 Days
• Field of Search: 530/350, 530/324, 530/329, 530/300, 514/12, 514/18
• US Class Current: 514/20.4
• CPC Class Codes: A61K 38/00 Medicinal preparations containing peptides peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00
• CPC Class Codes: A61P 11/00 Drugs for disorders of the respiratory system
• CPC Class Codes: A61P 17/00 Drugs for dermatological disorders
• CPC Class Codes: A61P 37/00 Drugs for immunological or allergic disorders
• CPC Class Codes: C07K 14/39 from yeasts
• CPC Class Codes: C07K 14/811 Serine protease (E.C. 3.4.21) inhibitors
• CPC Class Codes: C07K 16/38 against protease inhibitors of peptide structure
• CPC Class Codes: C07K 2319/02 containing a signal sequence
• CPC Class Codes: C12N 15/81 for yeasts

Abstract

Polypeptides, in particular the polypeptide of formula I: ##STR1## and analogues thereof which possess inhibitory activity against human leukocyte elastase. The polypeptides may be obtained by expression using plasmidic expression systems in hosts such as E. Coli and yeast, the polypeptide of formula I being also obtainable from psoriatic plaques.

Claims

1. An isolated polypeptide of Formula I Ala-Gln-Glu-Pro-Val-Lys-Gly-Pro-Val-Ser-Thr-Lys-Pro-Gly-Ser-Cys-Pro-Ile-Ile-Leu-Ile-Arg-Cys-Ala-Met-Leu-Asn-Pro-Pro-Asn-Arg-Cys-Leu-Lys-Asp-Thr-Asp-Cys-Pro-Gly-Ile-Lys-Lys-Cys-Cys-Glu-Gly-Ser-Cys-Gly-Met-Ala-Cys-Phe-Val-Pro-Gln.

2. A pharmaceutical composition comprising a polypeptide as defined in claim 1 in association with a pharmaceutically acceptable diluent or carrier.

3. A method of treating an elastase mediated disease in a warm-blooded animal or human comprising administering an effective amount of said polypeptide as defined in claim 1 to said warm-blooded animal or human.